TY  - JOUR

T1  - Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

JO  - PharmacoEconomics

UR  - https://eprints.whiterose.ac.uk/id/eprint/106724

UR  - http://dx.doi.org/10.1007/s40273-016-0436-6

PY  - 2016/08/01

AU  - Rafia R

AU  - Scope A

AU  - Harnan S

AU  - Stevens JW

AU  - Stevenson M

AU  - Lobo A

ED  - 

DO  - DOI: 10.1007/s40273-016-0436-6

PB  - Springer Verlag

Y2  - 2025/11/05

ER  -